NEW YORK, May 19, 2017 /PRNewswire/ -- Harwood
Feffer LLP (www.hfesq.com) is investigating potential claims
against the board of directors of Puma Biotechnology, Inc. ("Puma"
or the "Company") (NASDAQ: PBYI), concerning whether the board has
breached its fiduciary duties to shareholders.
Puma's 2015 Form 10-K disclosed that: "Based on pre-clinical
studies and clinical trials to date, we believe that neratinib may
offer an advantage over existing treatments that are used in the
treatment of patients with HER2-positive metastatic breast
cancer."
On May 4, 2017, Puma announced the
resignation of its Senior Vice President, Regulatory Affairs,
effective as of May 15, 2017, less
than two weeks before the FDA's scheduled review of neratinib.
On May 5, 2017, Fox Business
published an article reporting that a large number of patients
taking neratinib suffered from severe side effects, posing a safety
risk for the drug.
Our investigation concerns whether the Company board of
directors has breached its fiduciary duties to shareholders,
grossly mismanaged the Company, and/or committed abuses of control
in connection with the foregoing.
If you own Puma shares and wish to discuss this matter with us,
or have any questions concerning your rights and interests with
regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been
representing individual and institutional investors for many years,
serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website
(http://www.hfesq.com) for more information about the
firm.
Attorney Advertising. The law firm responsible for this
advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results
do not guarantee or predict a similar outcome with respect to any
future matter.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-puma-biotechnology-inc-300460923.html
SOURCE Harwood Feffer LLP